Please login to the form below

Not currently logged in
Email:
Password:

CureVac

This page shows the latest CureVac news and features for those working in and with pharma, biotech and healthcare.

CureVac to acquire Frame Cancer Therapeutics in €32m deal

CureVac to acquire Frame Cancer Therapeutics in €32m deal

The acquisition will advance CureVac’s oncology strategy and offers the potential to develop off-the-shelf and personalised cancer vaccines. ... CureVac, a German-based mRNA company, has announced its acquisition of Frame Cancer Therapeutics (Frame), a

Latest news

More from news
Approximately 22 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • COVID-19: the race to find a vaccine COVID-19: the race to find a vaccine

    BioNTech, CureVac and Translate Bio are also working on mRNA vaccines, while Pfizer and Sanofi are involved in those programmes through partnerships with BioNTech and Translate Bio, respectively.

  • Developing a COVID-19 vaccine Developing a COVID-19 vaccine

    The CEPI has currently initiated eight COVID-19 vaccine developments with Curevac, Inovio Pharmaceuticals, Moderna, Novavax, The University of Hong Kong, The University of Oxford, The University of Queensland and a

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    805. Curevac / Boehringer Ingelheim. Licence and collaboration. Messenger RNA vaccine (CV9202) in combination with afatininib and chemo-radiation for lung cancer.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Boehringer Ingelheim has taken a licence to Curevac's messenger RNA vaccine for one of its compounds and the Californian company, Sutro, has signed an early stage deal with Merck KGaA

  • Pharma deals during July 2014 Pharma deals during July 2014

    Scandinavia. CureVac's relationship with Sanofi Pasteur dates back to 2011 when the companies entered into a collaboration and option agreement covering mRNA-based vaccines generated using CureVac's RNActive technology ... CureVac is also eligible to

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • CureVac taps Klaus Edvardsen for chief development officer role CureVac taps Klaus Edvardsen for chief development officer role

    I am both honoured and excited to be joining CureVac at such an interesting point in its growth journey,” said Edvardsen. ... Their years of dedicated work on mRNA therapeutics positions CureVac well for bringing future treatments across a variety of

  • CureVac’s CEO appointed to EC High Level Group CureVac’s CEO appointed to EC High Level Group

    Dr Ingmar Hoerr, chief executive officer of clinical-stage mRNA technology specialist CureVac, has been appointed to the European Commission's High Level Group for research and innovation programmes. ... He brings 17 years of experience as the founder

  • CureVac appoints chief financial officer CureVac appoints chief financial officer

    Pierre Kemula joins the mRNA company’s management board. Tübingen, Germany-based mRNA firm CureVac has appointed Pierre Kemula as its new chief financial officer. ... Kemula will have responsibility for managing CureVac's financial and capital markets

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...